🌱 Tony's Memex Tony's Intertwingled Memex
Digital Garden | OER Curriculum
Home / Digital Garden / Continuous Intravenous Drug Infusion (Biomedical Engineering) Solution

Continuous Intravenous Drug Infusion (Biomedical Engineering) Solution

Problem Overview

We evaluate the continuous limit (nβ†’βˆžn \to \infty) of a discrete drug clearance concentration profile:

Cn(t)=C0(1+ktn)βˆ’nC_n(t) = C_0 \left(1 + \frac{k t}{n}\right)^{-n}
where C0=50.0Β mg/LC_0 = 50.0\text{ mg/L}, k=0.150Β hrβˆ’1k = 0.150\text{ hr}^{-1}, and t=8.0Β hrt = 8.0\text{ hr}. Direct substitution yields the indeterminate power form 1∞1^\infty. Using logarithmic transformation and L'HΓ΄pital's Rule, we prove convergence to continuous exponential decay C0eβˆ’ktC_0 e^{-kt}, compute blood serum levels, and discuss clinical pump safety.


Step-by-Step Mathematical Solution

Step 1: Logarithmic Transformation & Convergence Proof

The governing methodology is the Logarithmic Transformation Algorithm for Indeterminate Powers:

y=[f(n)]g(n)β€…β€ŠβŸΉβ€…β€Šln⁑y=g(n)ln⁑(f(n))β€…β€ŠβŸΉβ€…β€Šlim⁑y=elim⁑ln⁑yy = [f(n)]^{g(n)} \implies \ln y = g(n)\ln(f(n)) \implies \lim y = e^{\lim \ln y}
(This algorithm and its steps are defined in Indeterminate Powers and Logarithmic Transformation.)

  1. Classify the Indeterminate Form: As nβ†’βˆžn \to \infty, the base is 1+ktnβ†’11 + \frac{kt}{n} \to 1, while the exponent is βˆ’nβ†’βˆ’βˆž-n \to -\infty. This constitutes the indeterminate power form 1βˆ’βˆž=11∞1^{-\infty} = \frac{1}{1^\infty}, which is fundamentally of type 1∞1^\infty.

  2. Execute the Logarithmic Transformation: Let y=(1+ktn)βˆ’ny = \left(1 + \frac{kt}{n}\right)^{-n}. Taking the natural logarithm of both sides:

    ln⁑y=ln⁑[(1+ktn)βˆ’n]=βˆ’nln⁑(1+ktn)\ln y = \ln\left[\left(1 + \frac{kt}{n}\right)^{-n}\right] = -n \ln\left(1 + \frac{kt}{n}\right)
    As nβ†’βˆžn \to \infty, this takes the indeterminate product form βˆ’βˆžβ‹…ln⁑(1)=βˆ’βˆžβ‹…0-\infty \cdot \ln(1) = -\infty \cdot 0.

  3. Convert to a Quotient for L'HΓ΄pital's Rule: Push nn into the denominator as nβˆ’1=1nn^{-1} = \frac{1}{n}:

    lim⁑nβ†’βˆžln⁑y=lim⁑nβ†’βˆžβˆ’ln⁑(1+ktnβˆ’1)nβˆ’1\lim_{n \to \infty} \ln y = \lim_{n \to \infty} \frac{-\ln\left(1 + kt n^{-1}\right)}{n^{-1}}
    Direct substitution gives βˆ’ln⁑(1)0=00\frac{-\ln(1)}{0} = \frac{0}{0}. The conditions for L'HΓ΄pital's Rule are satisfied.

  4. Differentiate Numerator and Denominator with Respect to nn: Numerator derivative using the Chain Rule:

    ddn[βˆ’ln⁑(1+ktnβˆ’1)]=βˆ’11+ktnβˆ’1β‹…(βˆ’ktnβˆ’2)=ktnβˆ’21+ktn\frac{d}{dn}\left[-\ln\left(1 + kt n^{-1}\right)\right] = -\frac{1}{1 + kt n^{-1}} \cdot \left(-kt n^{-2}\right) = \frac{kt n^{-2}}{1 + \frac{kt}{n}}
    Denominator derivative using the Power Rule:
    ddn[nβˆ’1]=βˆ’nβˆ’2\frac{d}{dn}\left[n^{-1}\right] = -n^{-2}

  5. Evaluate the Limit of ln⁑y\ln y:

    lim⁑nβ†’βˆžln⁑y=L’Hlim⁑nβ†’βˆžktnβˆ’21+ktnβˆ’nβˆ’2=lim⁑nβ†’βˆž[βˆ’kt1+ktn]\lim_{n \to \infty} \ln y \overset{\text{L'H}}{=} \lim_{n \to \infty} \frac{\frac{kt n^{-2}}{1 + \frac{kt}{n}}}{-n^{-2}} = \lim_{n \to \infty} \left[-\frac{kt}{1 + \frac{kt}{n}}\right]
    As nβ†’βˆžn \to \infty, the term ktnβ†’0\frac{kt}{n} \to 0:
    L=lim⁑nβ†’βˆžln⁑y=βˆ’kt1+0=βˆ’ktL = \lim_{n \to \infty} \ln y = -\frac{kt}{1 + 0} = -kt

  6. Exponentiate to Recover the Original Limit:

    lim⁑nβ†’βˆžy=eL=eβˆ’kt\lim_{n \to \infty} y = e^L = e^{-kt}
    Multiplying by the initial concentration constant C0C_0:
    C(t)=lim⁑nβ†’βˆžCn(t)=C0eβˆ’ktC(t) = \lim_{n \to \infty} C_n(t) = C_0 e^{-kt}
    (Q.E.D. The discrete infusion model rigorously converges to continuous exponential clearance.)

Step 2: Numerical Concentration Comparison at t=8.0Β hourst = 8.0\text{ hours}

Given parameters: C0=50.0Β mg/LC_0 = 50.0\text{ mg/L}, k=0.150Β hrβˆ’1k = 0.150\text{ hr}^{-1}, and t=8.0Β hrt = 8.0\text{ hr}. The exponential factor is:

kt=(0.150)(8.0)=1.20kt = (0.150)(8.0) = 1.20

  1. Continuous Infusion Limit (nβ†’βˆžn \to \infty):

    C(8.0)=50.0β‹…eβˆ’1.20=50.0β‹…(0.301194)β‰ˆ15.06Β mg/LC(8.0) = 50.0 \cdot e^{-1.20} = 50.0 \cdot (0.301194) \approx 15.06\text{ mg/L}

  2. Low-Frequency Discrete Dosing (n=2Β boluses/hrn = 2\text{ boluses/hr}):

    C2(8.0)=50.0(1+1.202)βˆ’2=50.0(1+0.60)βˆ’2=50.0(1.60)βˆ’2=50.02.56β‰ˆ19.53Β mg/LC_2(8.0) = 50.0 \left(1 + \frac{1.20}{2}\right)^{-2} = 50.0 (1 + 0.60)^{-2} = 50.0 (1.60)^{-2} = \frac{50.0}{2.56} \approx 19.53\text{ mg/L}

    • Notice that the discrete delivery model over-predicts remaining circulating drug concentration by (19.53βˆ’15.06)/15.06β‰ˆ29.7%(19.53 - 15.06) / 15.06 \approx 29.7\%, illustrating that coarse discrete dosing models introduce severe kinetic error compared to continuous physiological clearance.

Step 3: Clinical Implications & Closed-Loop Control

  1. Saw-Tooth Spikes vs. Smooth Perfusion: In discrete bolus injections, drug concentration rises sharply to a toxic peak immediately after injection, then drops below the minimum effective concentration (MEC) before the next dose. This "saw-tooth" fluctuation risks toxic organ damage at the peak and therapeutic failure in the valley.
  2. Firmware Validation in Smart Pumps: Automated insulin pumps and anesthesia delivery controllers adjust stepper motors to administer hundreds of micro-units per minute, operating near the mathematical continuum nβ†’βˆžn \to \infty. By proving that lim⁑nβ†’βˆžCn(t)=C0eβˆ’kt\lim_{n \to \infty} C_n(t) = C_0 e^{-kt}, biomedical software engineers can safely program PID (proportional-integral-derivative) feedback loops based on clean exponential differential equations (Cβ€²(t)=βˆ’kC(t)C'(t) = -k C(t)) rather than complex, computationally intensive discrete recurrence relations.

Engineering Conclusion

In pharmacokinetic modeling, discrete dosing intervals create indeterminate forms of the type 1∞1^\infty as delivery frequency approaches continuous infusion. Direct intuition might erroneously suggest that 1∞=11^\infty = 1, which would imply the drug never clears from the patient's body!

Applying the 4-step Logarithmic Transformation Algorithm and L'HΓ΄pital's Rule proves that the base-exponent interaction yields an exact exponential decay factor eβˆ’kte^{-kt}. This derivation provides the foundational mathematical bridge connecting discrete medical device hardware (stepper motor pump pulses) to continuous physiological pharmacology, ensuring patients receive stable, life-saving therapeutic dosing within tight safety margins.